In the non-diabetes cohort, participants receiving the highest dose of retatrutide (12 mg weekly) achieved a mean body weight reduction of approximately 24% over 48 weeks a figure that substantially exceeds weight loss outcomes reported with currently approved agents at comparable timepoints
Saxenda still has its place, particularly for adolescents ages 12 and older, where it is the only GLP-1 currently approved
To avoid potential bias in assessing intergroup post-intervention differences, the analysis of covariance (ANCOVA) test was applied while adjusting for possible confounding factors, such as baseline values, age, changes in energy intake, physical activity, and BMI
Tirzepatide w/ B12 & glycine 60 mg (600 units)- $600 2 vials - 300 units each Tirzepatide w/ B12 & glycine 80 mg (800 units) - $750 2 vials - 400 units each This arrives as 2 vials of 30 mg each
10.1016/0376-8716(79)90040-1 173 LiX